Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Jun;9(2):328-337.
doi: 10.1177/23969873231219412. Epub 2024 Feb 26.

Incidence and clinical outcomes of perforations during mechanical thrombectomy for medium vessel occlusion in acute ischemic stroke: A retrospective, multicenter, and multinational study

Adam A Dmytriw  1   2 Basel Musmar  3 Hamza Salim  4 Sherief Ghozy  5 James E Siegler  6 Hassan Kobeissi  5 Hamza Shaikh  6 Jane Khalife  6 Mohamad Abdalkader  7 Piers Klein  7 Thanh N Nguyen  7 Jeremy J Heit  8 Robert W Regenhardt  1 Nicole M Cancelliere  2 Joshua D Bernstock  9 Kareem El Naamani  10 Abdelaziz Amllay  10 Lukas Meyer  11 Anne Dusart  12 Flavio Bellante  12 Géraud Forestier  13 Aymeric Rouchaud  13 Suzana Saleme  13 Charbel Mounayer  13 Jens Fiehler  11 Anna Luisa Kühn  14 Ajit S Puri  14 Christian Dyzmann  15 Peter T Kan  16 Marco Colasurdo  16   17 Gaultier Marnat  18 Jérôme Berge  18 Xavier Barreau  18 Igor Sibon  19 Simona Nedelcu  20 Nils Henninger  20   21   22 Thomas R Marotta  2 Christopher J Stapleton  1 James D Rabinov  1 Takahiro Ota  23 Shogo Dofuku  23 Leonard Ll Yeo  24 Benjamin Yq Tan  24   25 Anil Gopinathan  24   25 Juan Carlos Martinez-Gutierrez  26 Sergio Salazar-Marioni  26 Sunil Sheth  27 Leonardo Renieri  27 Carolina Capirossi  27 Ashkan Mowla  28 Lina Chervak  29 Achala Vagal  29 Nimer Adeeb  3 Hugo H Cuellar-Saenz  3 Stavropoula I Tjoumakaris  10 Pascal Jabbour  10 Priyank Khandelwal  30 Arundhati Biswas  31 Frédéric Clarençon  32   33 Mahmoud Elhorany  32   33   34 Kevin Premat  32   33 Iacopo Valente  35 Alessandro Pedicelli  35 João Pedro Filipe  36 Ricardo Varela  36 Miguel Quintero-Consuegra  37 Nestor R Gonzalez  37 Markus A Möhlenbruch  38 Jessica Jesser  38 Vincent Costalat  39 Adrien Ter Schiphorst  40 Vivek Yedavalli  41 Pablo Harker  42 Yasmin Aziz  42 Benjamin Gory  43   41 Christian Paul Stracke  44 Constantin Hecker  45 Ramanathan Kadirvel  5 Monika Killer-Oberpfalzer  45 Christoph J Griessenauer  45 Ajith J Thomas  6 Cheng-Yang Hsieh  46 David S Liebeskind  47 Răzvan Alexandru Radu  39 Andrea M Alexandre  35 Illario Tancredi  48 Tobias D Faizy  11 Robert Fahed  49 Charlotte Weyland  38 Boris Lubicz  50 Aman B Patel  1 Vitor Mendes Pereira  2 Adrien Guenego  50 MAD-MT Consortium
Affiliations
Multicenter Study

Incidence and clinical outcomes of perforations during mechanical thrombectomy for medium vessel occlusion in acute ischemic stroke: A retrospective, multicenter, and multinational study

Adam A Dmytriw et al. Eur Stroke J. 2024 Jun.

Abstract

Background: Mechanical thrombectomy (MT) has revolutionized the treatment of acute ischemic stroke (AIS) due to large vessel occlusion (LVO), but its efficacy and safety in medium vessel occlusion (MeVO) remain less explored. This multicenter, retrospective study aims to investigate the incidence and clinical outcomes of vessel perforations (confirmed by extravasation during an angiographic series) during MT for AIS caused by MeVO.

Methods: Data were collected from 37 academic centers across North America, Asia, and Europe between September 2017 and July 2021. A total of 1373 AIS patients with MeVO underwent MT. Baseline characteristics, procedural details, and clinical outcomes were analyzed.

Results: The incidence of vessel perforation was 4.8% (66/1373). Notably, our analysis indicates variations in perforation rates across different arterial segments: 8.9% in M3 segments, 4.3% in M2 segments, and 8.3% in A2 segments (p = 0.612). Patients with perforation had significantly worse outcomes, with lower rates of favorable angiographic outcomes (TICI 2c-3: 23% vs 58.9%, p < 0.001; TICI 2b-3: 56.5% vs 88.3%, p < 0.001). Functional outcomes were also worse in the perforation group (mRS 0-1 at 3 months: 22.7% vs 36.6%, p = 0.031; mRS 0-2 at 3 months: 28.8% vs 53.9%, p < 0.001). Mortality was higher in the perforation group (30.3% vs 16.8%, p = 0.008).

Conclusion: This study reveals that while the occurrence of vessel perforation in MT for AIS due to MeVO is relatively rare, it is associated with poor functional outcomes and higher mortality. The findings highlight the need for increased caution and specialized training in performing MT for MeVO. Further prospective research is required for risk mitigation strategies.

Keywords: AIS; MT; MeVo; Stroke; mechanical thrombectomy; perforation.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interestThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr. Regenhardt serves on a DSMB for a trial sponsored by Rapid Medical, serves as site PI for studies sponsored by Penumbra and Microvention, and receives stroke research grant funding from the National Institutes of Health, Society of Vascular and Interventional Neurology, and Heitman Stroke Foundation. Dr. Guenego reports consultancy for Rapid Medical and Phenox, not directly related to the present work. Prof. Clarençon reports conflicts of interest with Medtronic, Balt Extrusion (consultant), ClinSearch (core lab), Penumbra, Stryker (payment for reading), and Artedrone (Board); all not directly related to the present work. Dr. Henninger received support from NINDS NS131756, during the conduct of the study. Dr. Liebeskind is consultant as Imaging Core Lab to Cerenovus, Genentech, Medtronic, Stryker, Rapid Medical. Dr. Nguyen reports advisory board with Idorsia. Dr. Yeo reports Advisory work for AstraZeneca, Substantial support from NMRC Singapore and is a medical advisor for See-mode, Cortiro, and Sunbird Bio, with equity in Ceroflo. All unrelated to the present work. Dr. Griessenauer reports a proctoring agreement with Medtronic and research funding by Penumbra. Dr. Marnat reports conflicts of interest with Microvention Europe, Stryker Neurovascular, Balt (consulting), Medtronic, Johnson & Johnson, and Phenox (paid lectures), all not directly related to the present work. Pr Sibon reports conflict of interest with Medtronic, Sanofi, Bayer, Boehringer-Ingelheim, Novartis, Novo-Nordisk, BMS-Pfizer (board and paid lectures), all not directly related to the present work. Dr. Yedavalli is a consultant for RAPID (Ischemaview, Menlo Park, CA). Dr. Vagal is a consultant for Viz AI. She is also PI of Imaging core lab for ENDOLOW study funded by Cerenovus (monies go to the institution). Dr. Gopinathan reports conflicts of interest with Microvention, Stryker Neurovascular, Medtronic, BD, Penumbra (paid lectures, workshops, and proctoring), all not directly related to the present work. Dr. Bernstock has an equity position in Treovir Inc., an oHSV clinical stage company and UpFront Diagnostics. JDB is also on the Centile Bioscience and NeuroX1 boards of scientific advisors.

Figures

Graphical abstract
Graphical abstract
Figure 1.
Figure 1.
Sankey diagram depicts the transition of mRS scores before stroke versus 90 days after, grouped by perforation status. Colored streams represent the flow of patients from initial mRS scores (0–4) to 90-day outcomes (0–6).
Figure 2.
Figure 2.
Bar charts display the percentage distribution of 90-day modified Rankin Scale (mRS) scores for stroke patients.

References

    1. Sporns PB, Fiehler J, Ospel J, et al.. Expanding indications for endovascular thrombectomy-how to leave no patient behind. Ther Adv Neurol Disord. 2021; 14: 1756286421998905. - PMC - PubMed
    1. Goyal M, Menon BK, van Zwam WH, et al.. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet Lond Engl. 2016; 387(10029): 1723–1731. - PubMed
    1. ANZCTR – Registration. Randomized controlled trial of the clinical outcome and safety of endovascular versus standard medical therapy for stroke with medium sized vessel occlusion. 2023. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=1262... (accessed 13 November 2023).
    1. Saver JL, Chapot R, Agid R, et al.. Thrombectomy for distal, medium vessel occlusions: a consensus statement on present knowledge and promising directions. Stroke 2020; 51(9): 2872–2884. - PubMed
    1. Ospel JM, Goyal M. A review of endovascular treatment for medium vessel occlusion stroke. J Neurointerv Surg 2021; 13(7): 623–630. - PubMed

Publication types